Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care Setting

Inclusion Criteria: * Patient over 18 years of age being managed for MIMI, including * Systemic lupus * Gougerot-Sjögren's syndrome * Systemic scleroderma * Mixed connectivitis * Inflammatory myositis * Systemic sarcoidosis * Systemic vasculitis (necrotizing vasculitis and giant cell arteritis) * Behçet's disease * Adult Still's disease * IgG4-associated disease * Autoimmune cytopenias (autoimmune hemolytic anemia, immunological thrombocytopenic purpura, Evans syndrome) * Susac syndrome * Followed in the internal medicine department of Hôpital Bichat, Paris * Justifying VZV vaccination due to immunosuppression or age over 65. * Vaccinated as part of care between June 2025 and June 2026 * Regardless of history of shingles * With a serum sample available for analysis * Having received at least the first dose of the vaccine regimen (in hospital or in the community) Exclusion Criteria: * Evolving cancer, with or without treatment (chemotherapy, immunotherapy, etc.) * History of VZV vaccination (live or recombinant) * Patient who has had an allergic reaction to a vaccine * Pregnancy * Patient under legal protection, guardianship or trusteeship * Not affiliated to a social security scheme (general or CMU) * Patient unable to understand research information * Absence of non-opposition